Rationale for biologically active supplement Cartilox in the treatment of back pain

Back pain is a global medical and social problem. Pharmacotherapy of lower back pain is not always successful. Combined therapy allowing for better pain relief and counteracting progression of degenerative-dystrophic spine changes is of interest. The biologically active supplement (BAS) Cartilox, registered in the Russian Federation and containing a combination of collagen peptides (10 g), curcumin (Curcuma longa or Curcuma domestica) (0.125 g), Boswellia serrata extract (0.1 g containing acetyl-11-keto-β-boswellic acid (AKBA) 30%), black pepper extract (Piper nigrum) (0.025 g), sodium hyaluronate (0.0125 g), has been thoroughly studied for the treatment of osteoarthritis. We reviewed literature data regarding efficacy and safety of Cartilox and its components in patients with back pain. Available evidence base confirms efficacy and safety of Cartilox and its components in patients with back pain. Wider use of Cartilox as a part of comprehensive treatment can improve effectiveness and reduce the incidence of exacerbations in patients with low back pain. In turn, this will reduce the burden on healthcare system.